Abstract
Background: Long noncoding RNA (lncRNA) fetal-lethal non-coding developmental regulatory RNA (FENDRR), a newly known lncRNA, has been reported to be abnormally expressed in diverse tumors. This review is focused on clarifying the mechanism of FENDRR to regulate the biological process of tumors, affirming its value as a target for tumor therapy.
Methods: The pathophysiological mechanism of FENDRR acting on tumors has been analyzed and summarized by reviewing PubMed.
Results: The expression of lncRNA FENDRR is abnormally altered in clinical cancers, promoting the malignant transformation of a variety of tumors, including colon cancer, cervical cancer, hepatocellular carcinoma, prostate cancer, Malignant melanoma, lung cancer, osteosarcoma, breast cancer, etc. Cellular processions, including proliferation, invasion, apoptosis and migration affected by FENDRR, have been revealed.
Conclusion: Specific evidences for the involvement of LncRNA FENDRR in cancer regulatory processes suggest that FENDRR has the potential to be a biomarker or clinical therapeutic target for malignant tumors.
Keywords: Long non-coding RNA, FENDRR, cancer, biomarkers, therapeutic targets, clinical prognosis.
Current Pharmaceutical Design
Title:The Therapeutic Value and Molecular Mechanisms of lncRNA FENDRR in Human Cancer
Volume: 27 Issue: 39
Author(s): Wen Xu, Bei Wang, Yuxuan Cai, Jinlan Chen, Enqing Meng, Chong Guo, Gang Zhou*Chengfu Yuan*
Affiliation:
- College of Traditional Chinese Medicine, China Three Gorges University, Yichang 443002,China
- College of Medical Science, China Three Gorges University, Yichang 443002,China
Keywords: Long non-coding RNA, FENDRR, cancer, biomarkers, therapeutic targets, clinical prognosis.
Abstract:
Background: Long noncoding RNA (lncRNA) fetal-lethal non-coding developmental regulatory RNA (FENDRR), a newly known lncRNA, has been reported to be abnormally expressed in diverse tumors. This review is focused on clarifying the mechanism of FENDRR to regulate the biological process of tumors, affirming its value as a target for tumor therapy.
Methods: The pathophysiological mechanism of FENDRR acting on tumors has been analyzed and summarized by reviewing PubMed.
Results: The expression of lncRNA FENDRR is abnormally altered in clinical cancers, promoting the malignant transformation of a variety of tumors, including colon cancer, cervical cancer, hepatocellular carcinoma, prostate cancer, Malignant melanoma, lung cancer, osteosarcoma, breast cancer, etc. Cellular processions, including proliferation, invasion, apoptosis and migration affected by FENDRR, have been revealed.
Conclusion: Specific evidences for the involvement of LncRNA FENDRR in cancer regulatory processes suggest that FENDRR has the potential to be a biomarker or clinical therapeutic target for malignant tumors.
Export Options
About this article
Cite this article as:
Xu Wen , Wang Bei , Cai Yuxuan , Chen Jinlan, Meng Enqing, Guo Chong , Zhou Gang *, Yuan Chengfu *, The Therapeutic Value and Molecular Mechanisms of lncRNA FENDRR in Human Cancer, Current Pharmaceutical Design 2021; 27 (39) . https://dx.doi.org/10.2174/1381612827666210820094702
DOI https://dx.doi.org/10.2174/1381612827666210820094702 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design Targetting Esophageal and Gastric Cancers with Monoclonal Antibodies
Current Topics in Medicinal Chemistry MiRNA-29: A microRNA Family with Tumor-Suppressing and Immune-Modulating Properties
Current Molecular Medicine Notch Signalling Pathways and Their Importance in the Treatment of Cancers
Current Drug Targets Proteomics Approach to Illustrate Drug Action Mechanisms
Current Drug Discovery Technologies An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Design Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Thyroglobulin Determination in Fine Needle Aspiration Biopsy Washout of Suspicious Lymph Nodes in Thyroid Carcinoma Follow up
Endocrine, Metabolic & Immune Disorders - Drug Targets Radiopharmaceuticals in Tumor Hypoxia Imaging: A Review Focused on Medicinal Chemistry Aspects
Anti-Cancer Agents in Medicinal Chemistry Pharmacology of Rhein and Advancement in the Synthesis of Its Derivatives
Current Traditional Medicine Current Clinical Applications of Botulinum Toxin
Current Pharmaceutical Design Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design Integrins and Cancer: Gene Expression, Epigenetics and Metastasis
Current Genomics Biosystems Engineering of Prokaryotes with Tumor-Killing Capacities
Current Pharmaceutical Design Scalarane Sesterterpenoids
Current Bioactive Compounds Radiation and Gene Therapy: Rays of Hope for the New Millennium?
Current Gene Therapy Baicalin-induced Cytotoxicity and Apoptosis in Multidrug-resistant MC3/5FU Mucoepidermoid Carcinoma Cell Line
Letters in Drug Design & Discovery Cucurbitacins as Inducers of Cell Death and a Rich Source of Potential Anticancer Compounds
Current Pharmaceutical Design Advanced Microfluorescence Methods in Monitoring Intracellular Uptake of “Antisense” Oligonucleotides
Current Organic Chemistry Optimization of the Enzymolysis Conditions for Scorpion Peptides and Evaluation of its Antitumor Activity
Current Signal Transduction Therapy